Interview with Patrick Aghanian, General Manager, Sanofi Russia
There has been quite a bit of dynamism in the domestic pharmaceutical market since Focus Reports last look at the Russian market in 2006/2007. What have been the main changes…
Address: 125009, Россия, Москва ул. Тверская, дом 22 Бизнес центр ‘Саммит’ 8 этаж,Russia
Tel: +7 495 721 14 00
Web: http://www.sanofi.ru/l/ru/ru/index.jsp
Sanofi is a diversified global healthcare company focused on patients’ needs. Sanofi is a leader in emerging markets and one of the leading pharmaceutical companies in Europe, it is the world leader in human vaccines and animal health. The Group is present in 100 countries on five continents with almost 100,000 employees. Headquarter of the company is located in Paris.
Sanofi Russia has been present in Russia since 1970. Sanofi offers a large portfolio of original medicines, generics and OTC drugs in key therapeutic areas: diabetes, oncology, cardiovascular diseases, CNS diseases, internal medicine and thrombosis.
Vaccine production is one of Sanofi priorities. Sanofi Pasteur, the vaccine division of the Group, is the world leader in human vaccine production and development. Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. In 2008 it started inactivated polio vaccine production in co-operation with M.P. Chumakov Poliomyelitis and Viral Encephalitis Institute of the Russian Academy of Medical Science for the National Vaccination Calendar.
In March 2009 Zentiva, the leader in the generics segment in CEE markets, became a member of the Group.
In 2010 Sanofi acquired a modern insulin factory located in the Orel region. Sanofi-Aventis Vostok is company’s manufacturing facility for production of human insulin and insulin analogs in hi-tech pens in Russia. At this moment installed production lines can provide from 15 to 30 m. units of insulin dosed forms every year. It is planned to reach full capacity and full insulin production cycle (excuding production of active pharmaceutical ingredient, API) in early 2012.
Improvement of treatment of Russian patients is one of the key objectives of Sanofi group. The company supports large-scale national educational programs in all therapeutic areas. Sanofi launched over 190 specialized epilepsy centers (epicenters) fully equipped and operating as training centers for doctors, over 50 atherothrombosis schools (atheroschools) for doctors under support of the National Atherothrombosis Society. Starting from August 2009, the company has been carrying out all-Russia medico-social program “Help for Heart” to support patients who had instable angina (IA) or myocardial infarction (MI).
Starting from autumn 2009, Sanofi has been implementing all-Russia educational program for diabetes patients “Every day is yours” together with the leading Russian endocrinologists.
Starting from 2011 Sanofi Russia implements social program “Chance to life” aimed at improving the quality of life of women at early stages of breast cancer (BC). In the framework of this program Sanofi Russia will support 2000 patients with early stages of breast cancer supplying high quality medicine for up-to-date treatment in 2011. Starting from August 2011 Sanofi Russia together with the Health department of the Orel region and regional oncology center will start implementing breast cancer patients support program in the Orel region. In 2011 the program will cover 230 patients with BC who should receive chemotherapy with highly efficient modern drugs.Charitable activity of Sanofi Russia is consolidated by the program “Give a Smile”. Its aim is to help children from orphanages, to give orphans joy, warmth and smiles through attention and communication. Employees take an active part in the program. The program grew from single charity actions and in 2010 covered all Russian regions.
Sanofi offers a large portfolio of original medicines, generics and OTC drugs in key therapeutic areas: diabetes, oncology, cardiovascular diseases, CNS diseases, internal medicine and thrombosis.
There has been quite a bit of dynamism in the domestic pharmaceutical market since Focus Reports last look at the Russian market in 2006/2007. What have been the main changes…
You founded this business in 2003, and it has since grown to encompass five offices and over 250 experts. Can you tell our readers a bit about the history behind…
The following is an interview with Dr. Smirnov, as well as Dr. Dmitri Pavlovich, Director, Clinical Operations Russia Quintiles very recently announced the launch of its first commercial project in…
The following is an interview with Dr. Pavlovich, as well as Dr. Sergey Smirnov, Director, Business Development and Operations, CEE, CIS and Russia Quintiles very recently announced the launch of…
GSK CEO Andrew Witty has said that GSK must move away from selling “white pills in Western markets” in order to offset widespread generic erosion. This means diversifying the company’s…
The following is joint interview of Mr. Vayntrub and Regina Karymova, General Manager of Invar Mr. Vayntrub, you founded Invar in 1991, and began to capitalize on foreign investment in…
Pepeliaev, Goltsblat & Partners and the major UK firm Berwin Leighton Paisner (BLP). It calls itself the first international Russian law firm. Can you explain to our readers the rationale…
You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the…
You were working for GSK since 2003 before joining Galderma this year. Some within the industry might view Galderma as a step down from the third-ranked pharmaceutical company in the…
Janssen recently signed memorandums of understanding with both the Skolkovo Foundation and ChemRar. Can you describe the strategic parameters and intended outcomes of these agreements? How do they factor into…
Mr. Demidov, you are one of the pioneers of market research studies in Russia. There is a quote you like to use: ‘Market research is a business in the United…
How would you describe CMS’s own presence in the life sciences field in Russia, and what unique competitive advantages does the firm bring to this area of practice? Over the…
With the announcement of the Pharma 2020 strategy to develop the domestic pharmaceutical industry, multinational companies have pledged an excess of $1Bn in investment into local infrastructure. Servier, however, preempted…
See our Cookie Privacy Policy Here